Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter

Gene Therapy

Volumn 19, Issue 10, 2012, Pages 1018-1029

  Brendel, C ^a   Muller Kuller U ^a,b   Schultze Strasser, S ^a   Stein, S ^a   Chen Wichmann, L ^a   Krattenmacher, A ^a   Kunkel, H ^a   Dillmann, A ^a   Antoniou, M N ^c   Grez, M ^a  

^a Institute for Biomedical Research   (Germany)

^b GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

Lentiviral vector; Myeloid expression; Silencing; UCOE; X CGD

Indexed keywords

LENTIVIRUS VECTOR; MYELOID RELATED PROTEIN 8; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL LINE; CONTROLLED STUDY; EMBRYONAL CARCINOMA STEM CELL; EPIGENETICS; GENE EXPRESSION; GENE LOCUS; GENE THERAPY; GENE VECTOR; GENETIC REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METHYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE SPECIFICITY; TRANSGENE;

ANIMALS; CALGRANULIN A; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELLS, CULTURED; CHROMOSOMAL PROTEINS, NON-HISTONE; GENE SILENCING; GENES, ESSENTIAL; GENETIC VECTORS; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; LENTIVIRUS; MEMBRANE GLYCOPROTEINS; MICE; MICE, MUTANT STRAINS; MYELOID CELLS; NADPH OXIDASE; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC; TRANSGENES; UP-REGULATION;

EID: 84867402831     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.167     Document Type: Article

References (58)

1. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360: 447-458.
2. Boztug K, Schmidt M, Schwarzer A, Banerjee P, Avedillo Díez I, Dewey R et al. Successful hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. N Engl J Med 2010; 363: 1918-1927.
3. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010; 363: 355-364.
4. Gaspar HB, Bjorkegren E, Parsley K, Gilmour KC, King D, Sinclair J et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther 2006; 14: 505-513. (Pubitemid 44339393)
5. Sokolic R, Kesserwan C, Candotti F. Recent advances in gene therapy for severe congenital immunodeficiency diseases. CurrOpin Hematol 2008; 15: 375-380.
6. Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman MH et al. Insertional transformation ofhematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 2009; 17: 1919-1928.
7. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after genetherapyforchronic granulomatous disease. Nat Med2010; 16:198-204.
8. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U et al. Correction ofX-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-409.
9. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256. (Pubitemid 36077924)
10. Barde I, Laurenti E, Verp S, Wiznerowicz M, Offner S, Viornery A et al. Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease. Gene Therapy 2011; e-pub ahead of print 5 May 2011; doi:10.1038/gt.2011.65.
11. Santilli G, Almarza E, Brendel C, Choi U, Beilin C, Blundell MP et al. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther 2011; 19: 122-132.
12. Ellis J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther2005; 16: 1241 -1246. (Pubitemid 41611651)
13. Emery DW. The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. Hum Gene Ther 2011; 22: 761 -774.
14. Emery DW, Yannaki E, Tubb J, Stamatoyannopoulos G. A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc Natl Acad Sci USA 2000; 97: 9150-9155. (Pubitemid 30626689)
15. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987; 196: 261 -282. (Pubitemid 17122132)
16. Zhao Z, Han L. CpG islands: algorithms and applications in methylation studies. Biochem Biophys Res Commun 2009; 382: 643-645.
17. Bird A. The dinucleotide CG as a genomic signalling module. J Mol Biol2011; 409: 47-53.
18. Williams S, Mustoe T, Mulcahy T, Griffiths M, Simpson D, Antoniou M et al. CpG-island fragments from the HNRPA2B1/CBX3 genomic locus reduce silencing and enhance transgene expression from the hCMV promoter/enhancer in mammalian cells. BMC Biotechnol 2005; 5: 17.
19. Zhang F, Frost AR, Blundell MP, Bales O, Antoniou MN, Thrasher AJ. A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. Mol Ther 2010; 18: 1640-1649.
20. Senigl F, Plachy J, Hejnar J. The core element of a CpG island protects avian sarcoma and leukosis virus-derived vectors from transcriptional silencing. J Virol 2008; 82: 7818-7827.
21. Zhang F, Thornhill SI, Howe SJ, Ulaganathan M, Schambach A, Sinclair J et al. Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood 2007; 110: 1448-1457. (Pubitemid 47443959)
22. Antoniou M, Harland L, Mustoe T, Williams S, Holdstock J, Yague E et al. Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing. Genomics 2003; 82: 269-279. (Pubitemid 36952300)
23. Lindahl Allen M, Antoniou M. Correlation of DNA methylation with histone modifications across the HNRPA2B1-CBX3 ubiquitously-acting chromatin open element (UCOE). Epigenetics 2007; 2: 227-236. (Pubitemid 351308298)
24. Cullere X, Lauterbach M, Tsuboi N, Mayadas TN. Neutrophil-selective CD18 silencing using RNA interference in vivo. Blood 2008; 111: 3591 -3598.
25. Lagasse E, Clerc RG. Cloning and expression of two human genes encoding calcium-binding proteins that are regulated during myeloid differentiation. Mol Cell Biol 1988; 8: 2402-2410.
26. Lagasse E, Weissman IL. Mouse MRP8 and MRP14, two intracellular calcium-binding proteins associated with the development of the myeloid lineage. Blood 1992; 79: 1907-1915.
27. Lagasse E, Weissman IL. Bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages. J Exp Med 1994; 179: 1047-1052. (Pubitemid 24065666)
28. He J, Yang Q, Chang LJ. Dynamic DNA methylation and histone modifications contribute to lentiviral transgene silencing in murine embryonic carcinoma cells. J Virol 2005; 79: 13497-13508. (Pubitemid 41508162)
29. Harris RA, Wang T, Coarfa C, Nagarajan RP, Hong C, Downey SL et al. Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat Biotechnol 2010; 28: 1097-1105.
30. Hawkins RD, Hon GC, Lee LK, Ngo Q, Lister R, Pelizzola M et al. Distinct epigenomic landscapes of pluripotent and lineage-committed human cells. Cell Stem Cell 2010; 6: 479-491.
31. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 2008; 40: 897-903. (Pubitemid 351913645)
32. Li X, Zhao X, Fang Y, Jiang X, Duong T, Fan C et al. Generation of destabilized green fluorescent protein as a transcription reporter. J Biol Chem 1998; 273: 34970-34975. (Pubitemid 29028195)
33. Chang AH, Sadelain M. The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. Mol Ther 2007; 15: 445-456.
34. Kustikova OS, Schiedlmeier B, Brugman MH, Stahlhut M, Bartels S, Li Z et al. Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther 2009; 17: 1537-1547.
35. Zychlinski D, Schambach A, Modlich U, Maetzig T, Meyer J, Grassman E et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 2008; 16: 718-725. (Pubitemid 351426173)
36. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM et al. Inhibition of dendritic cell differentiation and accumulation ofmyeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205: 2235-2249.
37. Endoh Y, Chung YM, Clark IA, Geczy CL, Hsu K. IL-10-dependent S100A8 gene induction in monocytes/macrophages by double-stranded RNA. J Immunol 2009; 182: 2258-2268.
38. Nemeth J, Stein I, Haag D, Riehl A, Longerich T, Horwitz E et al. S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology 2009; 50: 1251-1262.
39. Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptorforadvanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010; 59: 249-255.
40. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006; 72: 1622-1631. (Pubitemid 44666730)
41. Perera C, McNeil HP, Geczy CL. S100 calgranulins in inflammatory arthritis. Immunol Cell Biol 2010; 88: 41 -49.
42. Hessian PA, Edgeworth J, Hogg N. MRP-8 and MRP-14, two abundant Ca(2+)-binding proteins of neutrophils and monocytes.J Leukoc Biol 1993; 53: 197-204.
43. Zentilin L, Qin G, Tafuro S, Dinauer MC, Baum C, Giacca M. Variegation of retroviral vector gene expression in myeloid cells. Gene Therapy2000; 7: 153-166. (Pubitemid 30088961)
44. Talbot GE, Waddington SN, Bales O, Tchen RC, Antoniou MN. Desmin-regulated lentiviral vectors for skeletal muscle gene transfer. Mol Ther 2010; 18: 601 -608.
45. Chambers SM, Boles NC, Lin KY, Tierney MP, Bowman TV, Bradfute SB et al. Hematopoietic fingerprints: an expression database of stem cells and their progeny. Cell Stem Cell 2007; 1: 578-591. (Pubitemid 350056409)
46. Palmer AC, Ahlgren-Berg A, Egan JB, Dodd IB, Shearwin KE. Potent transcriptional interference by pausing of RNA polymerases over a downstream promoter. Mol Cell 2009; 34: 545-555.
47. Gilchrist DA, Dos Santos G, Fargo DC, Xie B, Gao Y, Li L et al. Pausing of RNA polymerase II disrupts DNA-specified nucleosome organization to enable precise gene regulation.Cell2010; 143:540-551.
48. Hargreaves DC, Horng T, Medzhitov R. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 2009; 138: 129-145.
49. Ding C, Kume A, Bjorgvinsdottir H, Hawley RG, Pech N, Dinauer MC. High-level reconstitution of respiratory burst activity in a human X-linked chronic granulomatous disease (X-CGD) cell line and correction of murine X-CGD bone marrow cells by retroviral-mediated gene transfer of human gp91phox. Blood 1996; 88: 1834-1840. (Pubitemid 26307081)
50. Pollock JD, Williams DA, Gifford MA, Li LL, Du X, Fisherman J et al. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet 1995; 9: 202-209.
51. Zhang CC, Lodish HF. Murine hematopoietic stem cells change their surface phenotype during ex vivo expansion. Blood 2005; 105: 4314-4320. (Pubitemid 40723656)
52. Maetzig T, Brugman MH, Bartels S, Heinz N, Kustikova OS, Modlich U et al. Polyclonal fluctuation of lentiviral vector-transduced and expanded murine hematopoietic stem cells. Blood 2011; 117: 3053 - 3064.
53. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of immnodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002; 13: 803-813. (Pubitemid 34493974)
54. Schambach A, Bohne J, Baum C, Hermann FG, Egerer L, von Laer D et al. Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Therapy 2006; 13: 641 -645.
55. Moreno-Carranza B, Gentsch M, Stein S, Schambach A, Santilli G, Rudolf E et al. Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells. Gene Therapy 2009; 16: 111-118.
56. Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M et al. GeneCards version 3: the human gene integrator. Database (Oxford) 2010; 2010: baq020.
57. Stoesser G, Baker W, van den Broek A, Camon E, Garcia-Pastor M, Kanz C et al. The EMBL Nucleotide Sequence Database. Nucleic Acids Res 2002; 30: 21 -26. (Pubitemid 34679494)
58. Tonks A, Pearn L, Musson M, Gilkes A, Mills KI, Burnett AK et al. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia 2007; 21: 2495-2505. (Pubitemid 350148893)